Cargando…
Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs
INTRODUCTION: Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes a considerable burden for the patient and society. It is not clear yet whether aiming for remission (REM) is worthwhile, especially when compared with low disease activity (LDA). METHODS: In 356 consecutive RA pati...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979137/ https://www.ncbi.nlm.nih.gov/pubmed/24555808 http://dx.doi.org/10.1186/ar4491 |
_version_ | 1782310695041236992 |
---|---|
author | Radner, Helga Smolen, Josef S Aletaha, Daniel |
author_facet | Radner, Helga Smolen, Josef S Aletaha, Daniel |
author_sort | Radner, Helga |
collection | PubMed |
description | INTRODUCTION: Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes a considerable burden for the patient and society. It is not clear yet whether aiming for remission (REM) is worthwhile, especially when compared with low disease activity (LDA). METHODS: In 356 consecutive RA patients, we obtained data on physical function (health assessment questionnaire (HAQ)), health-related quality of life (HRQoL: Short Form 36 (SF36), Short Form 6 dimensions (SF-6D), Euro QoL 5D (EQ-5D)), work productivity (work productivity and activity impairment questionnaire (WPAI)), as well as estimation of direct and indirect costs. Cross-sectionally, data were compared in patients within different levels of disease activity according to the simplified disease activity index (SDAI; remission (REM ≤3.3); n = 87; low disease activity (LDA: 3.3 < SDAI ≤11); n = 103; moderate to high disease activity (MDA/HDA) >11 n = 119) by using analyses of variance (ANOVA). Longitudinal investigations assessed patients who changed from LDA to REM and vice versa. RESULTS: We found differences in patients achieving REM compared with LDA for HAQ (0.39 ± 0.58 versus 0.72 ± 68), WPAI (percentage impairment while working 11.8% ± 18.7% versus 26.8% ± 23.9%; percentage of overall activity impairment, 10.8% ± 14.1% versus 29.0% ± 23.6%)), EQ-5D (0.89 ± 0.12 versus 0.78 ± 0.6) and SF-36 (physical component score (PCS): 46.0 ± 8.6 versus 38.3 ± 10.5; mental component score (MCS): 49.9 ± 11.1 versus 47.9 ± 12.3) (P < 0.01 for all, except for SF36 MCS). Regarding costs, we found significant differences of direct and indirect costs (P < 0.05) within different levels of disease activity, with higher costs in patients with higher states of disease activity. Longitudinal evaluations confirmed the main analyses. CONCLUSION: Patients with REM show better function, HRQoL, and productivity, even when compared with another good state, such as LDA. Also from a cost perspective, REM appears superior to all other states. |
format | Online Article Text |
id | pubmed-3979137 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-39791372014-04-09 Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs Radner, Helga Smolen, Josef S Aletaha, Daniel Arthritis Res Ther Research Article INTRODUCTION: Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes a considerable burden for the patient and society. It is not clear yet whether aiming for remission (REM) is worthwhile, especially when compared with low disease activity (LDA). METHODS: In 356 consecutive RA patients, we obtained data on physical function (health assessment questionnaire (HAQ)), health-related quality of life (HRQoL: Short Form 36 (SF36), Short Form 6 dimensions (SF-6D), Euro QoL 5D (EQ-5D)), work productivity (work productivity and activity impairment questionnaire (WPAI)), as well as estimation of direct and indirect costs. Cross-sectionally, data were compared in patients within different levels of disease activity according to the simplified disease activity index (SDAI; remission (REM ≤3.3); n = 87; low disease activity (LDA: 3.3 < SDAI ≤11); n = 103; moderate to high disease activity (MDA/HDA) >11 n = 119) by using analyses of variance (ANOVA). Longitudinal investigations assessed patients who changed from LDA to REM and vice versa. RESULTS: We found differences in patients achieving REM compared with LDA for HAQ (0.39 ± 0.58 versus 0.72 ± 68), WPAI (percentage impairment while working 11.8% ± 18.7% versus 26.8% ± 23.9%; percentage of overall activity impairment, 10.8% ± 14.1% versus 29.0% ± 23.6%)), EQ-5D (0.89 ± 0.12 versus 0.78 ± 0.6) and SF-36 (physical component score (PCS): 46.0 ± 8.6 versus 38.3 ± 10.5; mental component score (MCS): 49.9 ± 11.1 versus 47.9 ± 12.3) (P < 0.01 for all, except for SF36 MCS). Regarding costs, we found significant differences of direct and indirect costs (P < 0.05) within different levels of disease activity, with higher costs in patients with higher states of disease activity. Longitudinal evaluations confirmed the main analyses. CONCLUSION: Patients with REM show better function, HRQoL, and productivity, even when compared with another good state, such as LDA. Also from a cost perspective, REM appears superior to all other states. BioMed Central 2014 2014-02-21 /pmc/articles/PMC3979137/ /pubmed/24555808 http://dx.doi.org/10.1186/ar4491 Text en Copyright © 2014 Radner et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
spellingShingle | Research Article Radner, Helga Smolen, Josef S Aletaha, Daniel Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs |
title | Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs |
title_full | Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs |
title_fullStr | Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs |
title_full_unstemmed | Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs |
title_short | Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs |
title_sort | remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979137/ https://www.ncbi.nlm.nih.gov/pubmed/24555808 http://dx.doi.org/10.1186/ar4491 |
work_keys_str_mv | AT radnerhelga remissioninrheumatoidarthritisbenefitoverlowdiseaseactivityinpatientreportedoutcomesandcosts AT smolenjosefs remissioninrheumatoidarthritisbenefitoverlowdiseaseactivityinpatientreportedoutcomesandcosts AT aletahadaniel remissioninrheumatoidarthritisbenefitoverlowdiseaseactivityinpatientreportedoutcomesandcosts |